Patent intelligence · AU
AU 2024276234
METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES
METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES
Patent details — AU 2024276234
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Dec 4, 2025
- Expiration
- Nov 29, 2045
- CPC classes
- A61K 47/ 68 A I, A61K/476803, A61K/4768037, A61K/476851
Quick answer
AU 2024276234 (METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES) is held by ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE]. Status: granted. Granted Dec 4, 2025. Expires Nov 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/476803, A61K/4768037, A61K/476851, A61K/476855, A61K/476857
More from ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2024342196
NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
granted -
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
granted -
US 20260035439
Anti-Sars-COV-2 Antibodies and Uses Thereof
granted -
EP 4670742
ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025333394
Tiparp Inhibitor Compounds
granted -
EP 4640274
LPAR1-INHIBITOREN
granted
Frequently asked questions
What is US patent 2024276234?
AU 2024276234 (METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES) is held by ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE]. Status: granted. Granted Dec 4, 2025. Expires Nov 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2024276234?
ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2024276234 expire?
Our index shows an expiration date of Nov 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.